Gilead Sciences Inc. (GILD) Shares Sold by DUPONT CAPITAL MANAGEMENT Corp
DUPONT CAPITAL MANAGEMENT Corp decreased its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 15.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 279,863 shares of the biopharmaceutical company’s stock after selling 50,613 shares during the period. Gilead Sciences accounts for 0.5% of DUPONT CAPITAL MANAGEMENT Corp’s holdings, making the stock its 28th largest position. DUPONT CAPITAL MANAGEMENT Corp’s holdings in Gilead Sciences were worth $22,143,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in GILD. Bank of New York Mellon Corp boosted its position in shares of Gilead Sciences by 4.0% in the second quarter. Bank of New York Mellon Corp now owns 26,617,229 shares of the biopharmaceutical company’s stock valued at $2,220,410,000 after buying an additional 1,023,299 shares in the last quarter. BlackRock Fund Advisors boosted its position in shares of Gilead Sciences by 2.6% in the second quarter. BlackRock Fund Advisors now owns 24,369,287 shares of the biopharmaceutical company’s stock valued at $2,032,886,000 after buying an additional 612,544 shares in the last quarter. Capital World Investors boosted its position in shares of Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock valued at $1,277,907,000 after buying an additional 3,380,000 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Gilead Sciences by 17.0% in the second quarter. Alliancebernstein L.P. now owns 13,346,714 shares of the biopharmaceutical company’s stock valued at $1,113,383,000 after buying an additional 1,942,138 shares in the last quarter. Finally, Parnassus Investments CA boosted its position in shares of Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock valued at $705,774,000 after buying an additional 2,640,284 shares in the last quarter. Hedge funds and other institutional investors own 73.59% of the company’s stock.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.13% during trading on Wednesday, reaching $74.77. The company’s stock had a trading volume of 2,294,684 shares. Gilead Sciences Inc. has a 52-week low of $71.39 and a 52-week high of $108.31. The stock has a market cap of $98.51 billion, a price-to-earnings ratio of 6.91 and a beta of 1.25. The stock’s 50 day moving average price is $74.54 and its 200-day moving average price is $80.07.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.87 by $0.12. The firm had revenue of $7.40 billion for the quarter, compared to analysts’ expectations of $7.47 billion. Gilead Sciences had a net margin of 47.74% and a return on equity of 100.57%. The business’s quarterly revenue was down 9.6% on a year-over-year basis. During the same period in the prior year, the business posted $3.22 earnings per share. Equities analysts anticipate that Gilead Sciences Inc. will post $11.47 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 29th. Investors of record on Thursday, December 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.51%. Gilead Sciences’s dividend payout ratio is 17.44%.
ILLEGAL ACTIVITY WARNING: “Gilead Sciences Inc. (GILD) Shares Sold by DUPONT CAPITAL MANAGEMENT Corp” was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2016/11/30/gilead-sciences-inc-gild-shares-sold-by-dupont-capital-management-corp.html.
GILD has been the subject of several research reports. Jefferies Group raised their price target on shares of Gilead Sciences from $91.00 to $93.00 and gave the stock a “buy” rating in a research note on Wednesday, October 5th. Piper Jaffray Cos. reissued a “buy” rating and issued a $108.00 target price on shares of Gilead Sciences in a research note on Monday, August 15th. Berenberg Bank began coverage on shares of Gilead Sciences in a research note on Thursday, September 22nd. They issued a “buy” rating for the company. Stifel Nicolaus began coverage on shares of Gilead Sciences in a research note on Monday, November 14th. They issued a “buy” rating and a $100.00 target price for the company. They noted that the move was a valuation call. Finally, Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 6th. Ten investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $97.90.
In related news, insider John C. Martin sold 100,000 shares of the firm’s stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $77.48, for a total transaction of $7,748,000.00. Following the transaction, the insider now directly owns 3,287,810 shares of the company’s stock, valued at approximately $254,739,518.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director John W. Madigan sold 105,000 shares of the firm’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $74.86, for a total value of $7,860,300.00. Following the transaction, the director now directly owns 121,761 shares in the company, valued at $9,115,028.46. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.